Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.
Immutrin has raised $87.1M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Immutrin's investors include Qiming Venture Partners, Parkwalk Advisors, SR One, Frazier Life Sciences, Cambridge Innovation Capital.
Immutrin is headquartered in Cambridge, United Kingdom.
Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.
Immutrin is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immutrin — Funding & Investors." VCBacked, March 24, 2026, https://www.vcbacked.co/company/immutrin. Accessed August 14, 2026.
VCBacked. (2026). Immutrin — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/immutrin
{{cite web |title=Immutrin — Funding & Investors |url=https://www.vcbacked.co/company/immutrin |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated